Thomas Struengmann
Tegernsee, Germany
Master of Business Administration, University of Augsburg | Master of Business Administration, University of Augsburg
Germany
pharmaceuticals, Self Made
$4,300,000,000
436
#436 Billionaires 2019
In 2005, Thomas Struengmann and twin Andreas sold their generic drug firm Hexal (plus a stake in Eon Labs) to Novartis for some $7 billion.They cofounded Hexal in 1986. The company launched highly successful versions of the cholesterol-lowering drug simvastatin.The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.Their venture portfolio includes Germany's BioNTech and Uruguay's Mega Pharma, initially a joint venture with Argentine billionaire Alberto Roemmers.In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.
After obtaining a business degree from the University of Augsburg, Thomas worked as a marketing manager for Schering-Plough.Like his twin brother, he is said to be an accomplished golfer and likes to ski. He reportedly collects modern art and Swiss watches.
69
4
Add a review